GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio
Shots:
- GSK to acquire IDRx incl. its lead candidate IDRX-42, for $1B upfront & ~$150M in regulatory milestones (total ~$1.15B). It will also pay success-based milestones & tiered royalties to Merck KGaA for IDRX-42
- IDRX-42 (TKI, small molecule) targets key KIT mutations, responsible for proliferation & survival of tumor cells, & is under P-I/Ib (StrateGIST 1) trial for 1L & 2L treatment of greater GIST & KIT mutated patients. GSK will expedite the development this year
- The study showed ORR of 29% (n=87, incl. 1 CR & 24 PRs) in efficacy-evaluable 2L patients & 53% (n=15, incl. 1 CR & 7PRs) in those who received 1L therapy; 2 PRs were awaiting verification at the cut off. Safety was favorable, with data highlighted at CTOS 2024
Ref: GSK | Image: IDRx
Related News:- GSK’s GSK’227 Secures the EMA’s Priority Medicines (PRIME) Designation for Extensive-Stage Small-cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
